Theravance Re-Introduces Vibativ In The U.S. Independently (For Now)
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech is bringing is long-plagued antibiotic back to U.S. patients, but is still searching for another company to help with commercialization efforts. Meanwhile, plans for its split and the launch of its partnered COPD drug are on track.